Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Neurogene (NGNE) over the last 4 years, with Sep 2025 value amounting to $127,000.

  • Neurogene's Capital Expenditures fell 28.65% to $127,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 39.59%. This contributed to the annual value of $808,000 for FY2024, which is 151.71% up from last year.
  • Neurogene's Capital Expenditures amounted to $127,000 in Q3 2025, which was down 14.19% from $148,000 recorded in Q2 2025.
  • In the past 5 years, Neurogene's Capital Expenditures registered a high of $780,000 during Q1 2025, and its lowest value of $29,000 during Q1 2023.
  • For the 3-year period, Neurogene's Capital Expenditures averaged around $198,545, with its median value being $128,000 (2023).
  • The largest annual percentage gain for Neurogene's Capital Expenditures in the last 5 years was 453.19% (2025), contrasted with its biggest fall of 61.46% (2025).
  • Over the past 3 years, Neurogene's Capital Expenditures (Quarterly) stood at $128,000 in 2023, then fell by 17.97% to $105,000 in 2024, then decreased by 28.65% to $127,000 in 2025.
  • Its Capital Expenditures stands at $127,000 for Q3 2025, versus $148,000 for Q2 2025 and $780,000 for Q1 2025.